Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 ...

UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the ...

Lotte Bjerre Knudsen, chief scientific advisor to the chief scientific officer, vice president of innovation and data ...

The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for ...

US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have ...

US pharma major Eli Lilly (NYSE: LLY) is accelerating manufacturing investment across Asia as the scramble to secure supply of high-demand GLP-1 therapies intensifies.

China/US biotech Vivatides Therapeutics has secured $54 million in an oversubscribed series A round, less than a year after launch, as it looks to break one of RNA medicine’s key constraints: delivery ...

US biotech Replimune (Nasdaq: REPL) has suffered a fresh blow after the US Food and Drug Administration rejected its lead cancer therapy RP1 (vusolimogene oderparepvec), sending shares sharply lower ...

The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11 years with inadequate response to ...

India’s push to expand global trade through Free Trade Agreements (FTAs) is opening up significant opportunities for the ...

The number of drug launches in Europe has fallen by around 35% in the 10 months since the USA introduced a new drug pricing policy, according to an analysis by the international research agency ...

German biotech BioNTech today announced positive results from the primary analysis of a Phase II cohort evaluating German ...